Advertisement

Search Results

Advertisement



Your search for it matches 15947 pages

Showing 15051 - 15100


prostate cancer
issues in oncology

Simulation Study Based on ERSPC Data Shows Greatest Cost-Effectiveness With Two to Three PSA Screenings Between 55 and 59 Years of Age

The European Randomized Study of Screening for Prostate Cancer (ERSPC) trial showed a significant 29% prostate cancer mortality reduction with prostate-specific antigen (PSA) screening but a marked negative impact on quality-adjusted life-years gained due to the effect of overdiagnosis on quality...

AACR Names Nancy E. Davidson, MD, President-Elect for 2015-2016

The American Association for Cancer Research (AACR) today announced the election of Nancy E. Davidson, MD, Director of the University of Pittsburgh Cancer Institute and UPMC CancerCenter in Pittsburgh, as its President-Elect for 2015–2016. Dr. Davidson will officially become President-Elect...

breast cancer

Neoadjuvant Chemotherapy for Breast Cancer Increases Chances of Lumpectomy, Decreases Chances of Mastectomy

Patients with larger malignant tumors of the breast who undergo chemotherapy before a breast cancer operation are more likely to undergo a lumpectomy than a mastectomy, according to a study published by Killelea et al in the Journal of the American College of Surgeons. Study investigators from...

leukemia
supportive care
issues in oncology

Inherited Gene Variation Leaves Young Leukemia Patients at Risk for Peripheral Neuropathy

St. Jude Children’s Research Hospital scientists have identified the first genetic variation that is associated with an increased risk and severity of peripheral neuropathy following treatment with a widely used anticancer drug. Investigators also found evidence of how it may be possible to...

issues in oncology

New Study Assesses Inclusion of Family in Cancer Patients’ Treatment Decisions

Family members often play an important role in providing care for patients with cancer, but which patients are more or less likely to involve family members in decisions regarding their care is not well known. A new study published by Hobbs et al in Cancer provides some insights and may help...

issues in oncology

FDA Approves First Biosimilar Product Filgrastim‑Sndz

The U.S. Food and Drug Administration (FDA) today approved filgrastim-sndz (Zarxio), the first biosimilar product approved in the United States. A biosimilar product is a biologic product that is approved based on a showing that it is highly similar to an already-approved biologic. The biosimilar...

cns cancers

Preclinical Study Shows Promise for the Development of Personalized Cellular Therapy for Brain Cancer

Immune cells engineered to seek out and attack a type of deadly brain cancer were found to be safe and effective at controlling tumor growth in mice that were treated with these modified cells, according a team from the Perelman School of Medicine at the University of Pennsylvania and the Novartis...

Harold Varmus, MD, Stepping Down as Director of the National Cancer Institute

Harold Varmus, MD, who has led the National Cancer Institute (NCI) at the National Institutes of Health (NIH) for nearly 5 years, has announced that he will step down from his post, effective March 31, 2015. Dr. Varmus will be joining Weill Cornell Medical College's faculty as the Lewis Thomas...

issues in oncology
legislation
issues in oncology

Study Finds Websites That Market Personalized Cancer Care Services Overemphasize Benefits

A recent analysis of 55 Internet websites marketing a broad range of tests and services that promise the ability to personalize cancer treatment has found that the websites often overemphasize their purported benefits and downplay their limitations. In addition, the study results show that the...

prostate cancer
issues in oncology

Early Study Shows Cabazitaxel May Be More Effective Than Docetaxel in Some Patients With Advanced Prostate Cancer

In a new study reported by de Leeuw et al in Clinical Cancer Research, researchers found that the novel taxane cabazitaxel (Jevtana) has properties that could make it more effective than docetaxel in some patients with advanced prostate cancer. This hypothesis is currently being tested in a phase...

gynecologic cancers
gynecologic cancers

Meta-Analysis Shows Increased Risk of Ovarian Cancer With Menopausal Hormone Therapy

In a study reported in The Lancet, the Collaborative Group on Epidemiological Studies of Ovarian Cancer found that use of menopausal hormone therapy was associated with an increased risk of ovarian cancer, with the risk being highest among current users. The study consisted of meta-analyses of...

cns cancers

Study Finds Improved Survival for Young Patients With Brain Metastases Who Receive Stereotactic Radiosurgery Alone

Cancer patients with limited brain metastases (one to four tumors) who are 50 years old and younger should receive stereotactic radiosurgery without whole-brain radiotherapy, according to a study by Saghal et al in the International Journal of Radiation Oncology • Biology • Physics....

prostate cancer

Sipuleucel-T Demonstrates Sustained Immune Response 2 Years After Treatment in Biochemically Recurrent Prostate Cancer

Preliminary results from the phase II STAND trial have demonstrated a robust immune response with sipuleucel-T (Provenge) that continues 2 years after completing treatment in men with biochemically recurrent prostate cancer. The findings, along with data from an ongoing phase IV registry related to ...

kidney cancer
kidney cancer

Adjuvant Sorafenib and Sunitinib Do Not Improve Outcomes in Locally Advanced Kidney Cancer

Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant sorafenib (Nexavar) or sunitinib (Sutent). The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery ...

solid tumors
prostate cancer
solid tumors

Men Who Have Had Testicular Cancer May Be More Likely to Develop Prostate Cancer

A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6%) than among those without a history of testicular cancer (2.8%). Men who have had testicular cancer were also more likely to develop...

prostate cancer

Early Evidence of Increase in Higher-Risk Prostate Cancers From 2011 to 2013

An analysis of data on roughly 87,500 men treated for prostate cancer since 2005 found a notable increase in higher-risk cases of the disease between 2011 and 2013. The retrospective analysis of patient data found the proportion of men diagnosed with intermediate- and high-risk disease increased by ...

multiple myeloma

FDA Approves Panobinostat Combination for the Treatment of Multiple Myeloma

The U.S. Food and Drug Administration (FDA) today approved panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma. Panobinostat is the first histone deacetylase (HDAC) inhibitor approved to treat multiple myeloma. It is...

breast cancer

Axillary Ultrasound After Neoadjuvant Chemotherapy for Node-Positive Breast Cancer Could Reduce Sentinel Lymph Node False-Negative Rate

In the American College of Surgeons Oncology Group Z1071 trial, sentinel lymph node surgery after neoadjuvant chemotherapy was associated with a 12.6% false-negative rate in breast cancer patients with cN1 disease. In an analysis of axillary ultrasound findings in the trial, a secondary endpoint,...

issues in oncology
issues in oncology

Study Shows That Previous Cancer ‘False Alarms’ May Discourage Patients From Screening Future Symptoms

Cancer researchers at University College London (UCL) have found that a cancer false alarm could discourage patients from checking out cancer symptoms they develop in the future. More than 80% of patients with potential cancer symptoms are given the all-clear after investigations. But according to ...

survivorship

Survivors of Childhood Cancer at Risk for Developing Hormone Deficiencies as Adults

Decades after undergoing cranial irradiation for childhood cancer, St. Jude Children's Research Hospital investigators found that adult survivors of pediatric cancer remain at risk for pituitary hormone deficiencies, which may diminish their health and quality of life. Chemaitilly et al published...

gynecologic cancers

12-Year Study Suggests Procedures to Prevent Cervical Cancer Do Not Affect Fertility

Common surgical procedures used to diagnose and treat precancerous cervical lesions do not decrease women's chances of becoming pregnant, according to a study conducted by Kaiser Permanente Northwest, which followed nearly 100,000 women for up to 12 years. In fact, researchers found that women ...

gynecologic cancers

Early Study Suggests Olaparib May Be Effective in Ovarian Cancers Expressing High Levels of POLQ

Last December, the U.S. Food and Drug Administration (FDA) approved olaparib (Lynparza) in the treatment of advanced ovarian cancer in women with BRCA1 or BRCA2 gene mutations. Now, a laboratory study by Ceccaldi et al has found that the drug may also be effective in breast and ovarian tumors that...

multiple myeloma
issues in oncology

‘Frailty Profile’ Predicts Survival and Toxicities Among Elderly Patients With Multiple Myeloma

A frailty score predicts mortality and the risk of toxicity in elderly patients with multiple myeloma and can be used to determine more suitable therapies for these patients, the International Myeloma Working Group reported in Blood. “Chronologic age, performance status, and physician's...

lung cancer
pancreatic cancer
issues in oncology

Chemotherapy Trials for Advanced Cancers of the Lung and Pancreas Overestimate Survival for Elderly Medicare Patients

Results of clinical trials evaluating chemotherapy regimens for advanced pancreatic cancer and lung cancers “tended to correctly estimate survival for Medicare patients aged 65 to 74 years, but to overestimate survival for older Medicare patients by 6 to 8 weeks,” Lamont et al reported...

head and neck cancer

FDA Approves Lenvatinib for Progressive Radioiodine-Refractory Differentiated Thyroid Cancer

The U.S. Food and Drug Administration (FDA) today granted approval to lenvatinib (Lenvima) to treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy. Lenvatinib is a tyrosine kinase inhibitor that binds to multiple sites...

head and neck cancer

Lenvatinib Shows Promise for Patients With Radioiodine-Refractory Thyroid Cancer in Phase III Study

In a phase III study led by researchers at The University of Texas MD Anderson Cancer Center, the oral antiangiogenic therapy lenvatinib has shown dramatic improvement in progression-free survival in patients with advanced radioiodine-refractory thyroid cancer. Their findings are published by...

lymphoma

Risk Assessment for Hodgkin Lymphoma Evolving, Promises Greater Precision and Specific Clinical Relevance

“Risk assessment in Hodgkin lymphoma is continuously evolving and promises even greater precision and specific clinical relevance in the future,” Joseph M. Connors, MD, stated in Blood. Dr. Connors is Clinical Professor, British Columbia Cancer Agency Centre for Lymphoid Cancer and the...

gynecologic cancers
gynecologic cancers

Adding Sorafenib to Standard Therapy of No Benefit in Advanced Ovarian Cancer, Study Reveals

In a study of women with stage III/IV epithelial ovarian cancer, the addition of sorafenib (Nexavar) to traditional paclitaxel/carboplatin therapy resulted in no greater efficacy and increased toxicity, according to a report by Hainsworth et al in Cancer Medicine. The investigators suggested that...

palliative care
supportive care
palliative care

Study Identifies Eight Signs Associated With Impending Death in Cancer Patients

Researchers at The University of Texas MD Anderson Cancer Center have identified eight highly specific physical and cognitive signs associated with imminent death in cancer patients. The findings, published by Hui et al in Cancer, could offer clinicians the ability to better communicate with...

lymphoma

Phase III Study Shows Significant Benefit of Obinutuzumab in Refractory Indolent Non-Hodgkin Lymphoma

In a preplanned interim analysis of the phase III GADOLIN trial, obinutuzumab (Gazyva) plus bendamustine (Trenada) followed by obinutuzumab alone was found to significantly improve progression-free survival compared to bendamustine alone in patients with indolent, refractory non-Hodgkin lymphoma....

pancreatic cancer

Reduced Use of Radiotherapy for Unresectable Pancreatic Adenocarcinoma in the United States

In a study reported in a research letter in JAMA Surgery, Shapiro et al found that use of radiotherapy in unresectable pancreas cancer has decreased over time and that disparities in use can be identified. Decreasing Use The study involved Surveillance, Epidemiology, and End Results (SEER) data...

prostate cancer
issues in oncology

Widespread Use of Docetaxel Preceded Phase III Evidence of Usefulness in Patients With Metastatic Prostate Cancer

Docetaxel was being widely used by patients with metastatic prostate cancer before phase III evidence that it was more effective than standard-of-care for patients with castration-resistant prostate cancer, according to an analysis of Medicare claims from before and after the trial results and...

breast cancer
supportive care
issues in oncology

Women Who Undergo Delayed Breast Reconstruction May Experience More Cancer‑Related Distress Than Women Who Undergo Mastectomy Alone

In women who have undergone mastectomy, those who underwent delayed breast reconstruction experienced greater cancer-related distress over the long term compared with women who underwent mastectomy alone, according to a prospective study by Metcalfe et al in the Journal of Surgical Oncology. For...

leukemia
lymphoma
issues in oncology

Study Shows Immunosuppressives, Chemotherapy May Reactivate Hepatitis B

Individuals previously infected with the hepatitis B virus (HBV) that receive chemotherapy or immunosuppressive treatment may be at risk of reactivating the virus, according to a report published by Di Bisceglie et al in Hepatology. Reactivation of HBV can be fatal, and researchers suggest routine...

lung cancer
issues in oncology
issues in oncology
cost of care

Genetic Screening Deemed Cost-Effective in
Non–Small Cell Lung Cancer

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements, and subsequent biomarker-guided treatment, is cost-effective compared with standard chemotherapy treatment without any molecular testing in the metastatic...

issues in oncology

Study Identifies New Pathway for Stalling BRCA-Mutated Tumor Growth in Mice and Human Cells

Inhibiting the action of a particular enzyme dramatically slows the growth of tumor cells tied to BRCA1 and BRCA2 genetic mutations that are closely tied to breast and ovarian cancers, according to researchers at New York University (NYU) Langone Medical Center. Senior investigator Agnel Sfeir,...

breast cancer

FDA Approves Palbociclib in Combination With Letrozole for Advanced Breast Cancer

The U.S. Food and Drug Administration has granted accelerated approval to palbociclib (Ibrance) in combination with letrozole for the treatment of postmenopausal women with estrogen receptor–positive, HER2-negative metastatic breast cancer who have not yet received an endocrine-based therapy. ...

issues in oncology

Study Sheds New Light on Syndrome Associated With Aggressive Pediatric Cancer

A new study involving researchers at The University of Nottingham has revealed how children with an aggressive cancer predisposition syndrome experience a never-before- seen flood of mutations in their disease in very short periods of time. The findings were published by Shlien et al in Nature...

supportive care

ASCO Clinical Practice Guideline Update 2014: No Change to 2013 Venous Thromboembolism Prophylaxis and Treatment Guideline

As reported in the Journal of Clinical Oncology by Lyman et al, an ASCO update committee recommended no changes to the 2013 clinical practice guideline for venous thromboembolism (VTE) prophylaxis and treatment after review of 53 new publications in the area that became available between...

issues in oncology
pancreatic cancer
issues in oncology

Study Finds Biologic Markers Associated With High-Risk Pancreatic Lesions

Pancreatic cancer affects approximately 46,000 people each year in the United States, and ranks fourth among the leading causes of cancer-related deaths. Only about 6% of individuals with pancreatic cancer will live 5 years after their diagnosis. One reason for this high mortality rate is the lack...

lung cancer

FDA Grants Breakthrough Therapy Designation to MPDL3280A for Non–Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Genentech’s investigational cancer immunotherapy MPDL3280A for the treatment of PD-L1–positive non–small cell lung cancer (NSCLC) that has progressed during or after platinum-based...

breast cancer
issues in oncology

California Primary Care Physicians Struggle to Adapt to Breast Density Law, Study Shows

Ten months after California legislators enacted a controversial law mandating that radiologists notify women if they have dense breast tissue, University of California (UC), Davis researchers have found that half of primary care physicians are still unfamiliar with the law, and many don't feel...

prostate cancer
issues in oncology

High-Risk Prostate Cancer Detection More Likely With Targeted MRI/Ultrasound Fusion Technique Than With Standard Biopsy

Targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer, according to a study by Siddiqui et al published in JAMA. More than 1,000 men participated in the research at the ...

gynecologic cancers
issues in oncology

Researchers Pinpoint Two Genes That Trigger Most Severe Form of Ovarian Cancer

Researchers at University of North Carolina School of Medicine have created the first mouse model of the most aggressive form of ovarian cancer and found a potential route to better treatments and much-needed diagnostic screens. Led by Terry Magnuson, PhD, the Sarah Graham Kenan Professor and Chair ...

leukemia
issues in oncology

Protein-Based Therapy Shows Promise Against Resistant ALL in Preclinical Study

Chemotherapy resistance is one of the most formidable obstacles to treating acute lymphoblastic leukemia (ALL), the most common form of childhood cancer. Now researchers at Children’s Hospital Los Angeles (CHLA) have designed and developed a new protein-based therapy that may prove highly...

colorectal cancer
issues in oncology

Study Finds Fear of Cancer Can Be Either a Facilitator or Deterrent to Getting Colorectal Cancer Screenings

People who worry a lot about cancer are more likely to want to get screened for colon cancer—perhaps due to a desire for reassurance—but having a more visceral negative response to thinking about cancer acted as a deterrent to actually getting screened, according to a British study by...

head and neck cancer
issues in oncology

Study Uncovers Range of Molecular Alterations in Head and Neck Squamous Cell Carcinomas, New Potential Drug Targets

Investigators with The Cancer Genome Atlas (TCGA) Research Network have discovered genomic differences—with potentially important clinical implications—in human papillomavirus (HPV)-associated head and neck cancers. These findings were reported in Nature. The researchers also uncovered ...

prostate cancer

Testosterone Therapy May Help Some Men With Castration-Resistant Prostate Cancer

According to researchers at the Johns Hopkins Kimmel Cancer Center, testosterone, which is generally thought to be a feeder of prostate cancer, has been found to suppress some advanced prostate cancers. The hormone may also reverse resistance to testosterone-blocking drugs used to treat prostate...

issues in oncology
prostate cancer
issues in oncology

Analysis of Unexplored Part of Human Genome May Lead to Cancer Biomarker Development

A new analysis opens the door to the discovery of thousands of potential new cancer biomarkers, according to a recent study by Iyer et al published in Nature Genetics. Long Noncoding RNA Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of long...

breast cancer
issues in oncology

New Breast Exam Nearly Quadruples Detection of Invasive Breast Cancers When Added to Screening Mammography in Women With Dense Breast Tissue

A new breast imaging technique developed at Mayo Clinic nearly quadruples detection rates of invasive breast cancers in women with dense breast tissue, according to the results of a study published by Rhodes et al in the American Journal of Roentgenology. What Is MBI? Molecular breast imaging...

Advertisement

Advertisement




Advertisement